Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial

P. M. Battezzati, M. Podda, F. B. Bianchi, R. Naccarato, F. Orlandi, C. Surrenti, L. Pagliaro, F. Manenti

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

The administration of ursodeoxycholic acid, a hydrophilic bile acid not hepatotoxic to humans, has been suggested for treatment of primary biliary cirrhosis to improve cholestasis and reduce hepatocellular damage. Efficacy of treatment has been studied mainly in patients with asymptomatic or early-stage disease. In January 1988, to establish the efficacy and safety of ursodeoxycholic acid in a population with more severe disease, we started a multicenter, double-blind, placebo-controlled trial in patients with symptomatic disease, that is, with pruritus or serum bilirubin exceeding 2 mg/dl. Forty-four patients were assigned to ursodeoxycholic acid, 500 mg daily (corresponding to about 8.7 mg/kg body weight in these patients), and 44 to a placebo. As planned at the beginning of the study, a preliminary analysis was performed when all patients had been followed for at least 6 months (33 patients up to 12 months). Pruritus, self-evaluated by the patients, and cholestyramine consumption, as recorded in a diary, decreased significantly (p <0.01) in both groups. In patients who initially had abnormal levels, serum bilirubin decreased significantly (p <0.05) in the ursodeoxycholic acid group compared to placebo. After 6 months the following were also significantly better in the ursodeoxycholic acid than in the placebo group: a composite weighted biochemical index taking into account the changes in serum bilirubin, alkaline phosphatase, γ-GT and AST (p <0.001); serum prealbumin (p <0.05); IgG (p <0.01) and IgM (p <0.01) levels. The positive effects of ursodeoxycholic acid administration on serum bilirubin, the most important prognostic factor in primary biliary cirrhosis, and on liver protein synthesis suggest that ursodeoxycholic acid may be useful for patients with more advanced disease than those so far included in therapeutic trials.

Original languageEnglish
Pages (from-to)332-338
Number of pages7
JournalJournal of Hepatology
Volume17
Issue number3
DOIs
Publication statusPublished - 1993

Fingerprint

Ursodeoxycholic Acid
Biliary Liver Cirrhosis
Multicenter Studies
Bilirubin
Placebos
Serum
Pruritus
Cholestyramine Resin
Prealbumin
Cholestasis
Bile Acids and Salts
Alkaline Phosphatase
Immunoglobulin M
Immunoglobulin G
Body Weight
Safety

Keywords

  • Bile acids
  • Chronic cholestasis
  • Icteric
  • Primary biliary cirrhosis
  • Pruritus
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. / Battezzati, P. M.; Podda, M.; Bianchi, F. B.; Naccarato, R.; Orlandi, F.; Surrenti, C.; Pagliaro, L.; Manenti, F.

In: Journal of Hepatology, Vol. 17, No. 3, 1993, p. 332-338.

Research output: Contribution to journalArticle

Battezzati, PM, Podda, M, Bianchi, FB, Naccarato, R, Orlandi, F, Surrenti, C, Pagliaro, L & Manenti, F 1993, 'Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial', Journal of Hepatology, vol. 17, no. 3, pp. 332-338. https://doi.org/10.1016/S0168-8278(05)80214-4
Battezzati, P. M. ; Podda, M. ; Bianchi, F. B. ; Naccarato, R. ; Orlandi, F. ; Surrenti, C. ; Pagliaro, L. ; Manenti, F. / Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial. In: Journal of Hepatology. 1993 ; Vol. 17, No. 3. pp. 332-338.
@article{2b356aa69e5b47a99eb5fd1100e5a2ff,
title = "Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial",
abstract = "The administration of ursodeoxycholic acid, a hydrophilic bile acid not hepatotoxic to humans, has been suggested for treatment of primary biliary cirrhosis to improve cholestasis and reduce hepatocellular damage. Efficacy of treatment has been studied mainly in patients with asymptomatic or early-stage disease. In January 1988, to establish the efficacy and safety of ursodeoxycholic acid in a population with more severe disease, we started a multicenter, double-blind, placebo-controlled trial in patients with symptomatic disease, that is, with pruritus or serum bilirubin exceeding 2 mg/dl. Forty-four patients were assigned to ursodeoxycholic acid, 500 mg daily (corresponding to about 8.7 mg/kg body weight in these patients), and 44 to a placebo. As planned at the beginning of the study, a preliminary analysis was performed when all patients had been followed for at least 6 months (33 patients up to 12 months). Pruritus, self-evaluated by the patients, and cholestyramine consumption, as recorded in a diary, decreased significantly (p <0.01) in both groups. In patients who initially had abnormal levels, serum bilirubin decreased significantly (p <0.05) in the ursodeoxycholic acid group compared to placebo. After 6 months the following were also significantly better in the ursodeoxycholic acid than in the placebo group: a composite weighted biochemical index taking into account the changes in serum bilirubin, alkaline phosphatase, γ-GT and AST (p <0.001); serum prealbumin (p <0.05); IgG (p <0.01) and IgM (p <0.01) levels. The positive effects of ursodeoxycholic acid administration on serum bilirubin, the most important prognostic factor in primary biliary cirrhosis, and on liver protein synthesis suggest that ursodeoxycholic acid may be useful for patients with more advanced disease than those so far included in therapeutic trials.",
keywords = "Bile acids, Chronic cholestasis, Icteric, Primary biliary cirrhosis, Pruritus, Ursodeoxycholic acid",
author = "Battezzati, {P. M.} and M. Podda and Bianchi, {F. B.} and R. Naccarato and F. Orlandi and C. Surrenti and L. Pagliaro and F. Manenti",
year = "1993",
doi = "10.1016/S0168-8278(05)80214-4",
language = "English",
volume = "17",
pages = "332--338",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "3",

}

TY - JOUR

T1 - Ursodeoxycholic acid for symptomatic primary biliary cirrhosis. Preliminary analysis of a double-blind multicenter trial

AU - Battezzati, P. M.

AU - Podda, M.

AU - Bianchi, F. B.

AU - Naccarato, R.

AU - Orlandi, F.

AU - Surrenti, C.

AU - Pagliaro, L.

AU - Manenti, F.

PY - 1993

Y1 - 1993

N2 - The administration of ursodeoxycholic acid, a hydrophilic bile acid not hepatotoxic to humans, has been suggested for treatment of primary biliary cirrhosis to improve cholestasis and reduce hepatocellular damage. Efficacy of treatment has been studied mainly in patients with asymptomatic or early-stage disease. In January 1988, to establish the efficacy and safety of ursodeoxycholic acid in a population with more severe disease, we started a multicenter, double-blind, placebo-controlled trial in patients with symptomatic disease, that is, with pruritus or serum bilirubin exceeding 2 mg/dl. Forty-four patients were assigned to ursodeoxycholic acid, 500 mg daily (corresponding to about 8.7 mg/kg body weight in these patients), and 44 to a placebo. As planned at the beginning of the study, a preliminary analysis was performed when all patients had been followed for at least 6 months (33 patients up to 12 months). Pruritus, self-evaluated by the patients, and cholestyramine consumption, as recorded in a diary, decreased significantly (p <0.01) in both groups. In patients who initially had abnormal levels, serum bilirubin decreased significantly (p <0.05) in the ursodeoxycholic acid group compared to placebo. After 6 months the following were also significantly better in the ursodeoxycholic acid than in the placebo group: a composite weighted biochemical index taking into account the changes in serum bilirubin, alkaline phosphatase, γ-GT and AST (p <0.001); serum prealbumin (p <0.05); IgG (p <0.01) and IgM (p <0.01) levels. The positive effects of ursodeoxycholic acid administration on serum bilirubin, the most important prognostic factor in primary biliary cirrhosis, and on liver protein synthesis suggest that ursodeoxycholic acid may be useful for patients with more advanced disease than those so far included in therapeutic trials.

AB - The administration of ursodeoxycholic acid, a hydrophilic bile acid not hepatotoxic to humans, has been suggested for treatment of primary biliary cirrhosis to improve cholestasis and reduce hepatocellular damage. Efficacy of treatment has been studied mainly in patients with asymptomatic or early-stage disease. In January 1988, to establish the efficacy and safety of ursodeoxycholic acid in a population with more severe disease, we started a multicenter, double-blind, placebo-controlled trial in patients with symptomatic disease, that is, with pruritus or serum bilirubin exceeding 2 mg/dl. Forty-four patients were assigned to ursodeoxycholic acid, 500 mg daily (corresponding to about 8.7 mg/kg body weight in these patients), and 44 to a placebo. As planned at the beginning of the study, a preliminary analysis was performed when all patients had been followed for at least 6 months (33 patients up to 12 months). Pruritus, self-evaluated by the patients, and cholestyramine consumption, as recorded in a diary, decreased significantly (p <0.01) in both groups. In patients who initially had abnormal levels, serum bilirubin decreased significantly (p <0.05) in the ursodeoxycholic acid group compared to placebo. After 6 months the following were also significantly better in the ursodeoxycholic acid than in the placebo group: a composite weighted biochemical index taking into account the changes in serum bilirubin, alkaline phosphatase, γ-GT and AST (p <0.001); serum prealbumin (p <0.05); IgG (p <0.01) and IgM (p <0.01) levels. The positive effects of ursodeoxycholic acid administration on serum bilirubin, the most important prognostic factor in primary biliary cirrhosis, and on liver protein synthesis suggest that ursodeoxycholic acid may be useful for patients with more advanced disease than those so far included in therapeutic trials.

KW - Bile acids

KW - Chronic cholestasis

KW - Icteric

KW - Primary biliary cirrhosis

KW - Pruritus

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0027309033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027309033&partnerID=8YFLogxK

U2 - 10.1016/S0168-8278(05)80214-4

DO - 10.1016/S0168-8278(05)80214-4

M3 - Article

VL - 17

SP - 332

EP - 338

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 3

ER -